Harmony Biosciences presents Phase 3 HBS-301 trial data in narcolepsy, idiopathic hypersomnia at European Narcolepsy Days

• Harmony Biosciences set a poster presentation on Phase 3 trials of investigational HBS-301 at European Narcolepsy Days in Bern.
• Results have not been presented yet; the poster is scheduled for Oct. 2 and Oct. 3, 2026.
• HBS-301 is a high-dose, optimized enteric-coated pitolisant tablet formulation being developed for excessive daytime sleepiness in narcolepsy.
• The program also targets idiopathic hypersomnia, with Phase 3 studies running in adult patients across ONSTRIDE-1 and ONSTRIDE-2.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Harmony Biosciences Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610010805PRIMZONEFULLFEED9837476) on October 01, 2026, and is solely responsible for the information contained therein.